Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates

Matsumoto, Kensaku; Kuwata, Takeo; Tolbert, W.D.; Richard, Jonathan; Ding, Shilei; Prévost, Jérémie; Takahama, Shokichi; Judicate, George P; Ueno, Takamasa; Nakata, Hirotomo; Kobayakawa, Takuya; Tsuji, Kohei; Tamamura, Hirokazu; Smith, Amos B.; Pazgier, M.; Finzi, Andrés; Matsushita, Shuzo

doi:10.1128/jvi.01638-22

Cited by 1 publication

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, Anti-CD4i singlechain variable fragments, which consist of variable regions of antibody, bind and inhibit most HIV-1 strains from various clades, although only the small fragments of antibody are accessible to CD4i epitope [19]. In addition, anti-CD4i Abs mediate ADCC against various HIV-1 strains, especially in the presence of CD4-mimetic compound [20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Idiotopes of antibodies against HIV‐1 CD4‐induced epitope shared with those against microorganisms

Biswas,

Kuwata,

Yamauchi

et al. 2023

Immunology

Self Cite

View full text Add to dashboard Cite

Induction of antibodies (Abs) against the conformational CD4‐induced (CD4i) epitope is frequent in HIV‐1 infection. However, the mechanism of development of anti‐CD4i Abs is unclear. We used anti‐idiotypic (aID) monoclonal Abs (mAbs) of anti‐CD4i mAbs to isolate anti‐CD4i mAbs from infected subjects and track the causative antigens. One anti‐aID mAb sorted from infected subjects by aID mAbs had the characteristics of anti‐CD4i Abs, including IGHV1‐69 usage and ability to bind to HIV‐1 Env enhanced by sCD4. Critical amino acid sequences for the binding of six anti‐aID mAbs, with shared idiotope to anti‐CD4i mAbs, were analysed by phage display. The identified amino acid sequences showed similarity to proteins from human microbiota and infectious agents. Peptides synthesized from Caudoviricetes sp and Vibrio vulnificus based on the identified sequences were reactive to most anti‐aID and some anti‐CD4i mAbs. These results suggest that anti‐CD4i Abs may evolve from B cells primed by microorganisms.

show abstract